Latest Insider Transactions at Allogene Therapeutics, Inc. (ALLO)
This section provides a real-time view of insider transactions for Allogene Therapeutics, Inc. (ALLO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Allogene Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Allogene Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2021
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.16%
|
$10,000
$2.27 P/Share
|
|
Jun 11
2021
|
Joshua A Kazam |
SELL
Bona fide gift
|
Direct |
500,000
-67.21%
|
-
|
|
Jun 10
2021
|
Joshua A Kazam |
BUY
Grant, award, or other acquisition
|
Direct |
16,498
+2.17%
|
-
|
|
Jun 10
2021
|
Franz B Humer Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,498
+10.05%
|
-
|
|
Jun 09
2021
|
Owen N. Witte |
SELL
Open market or private sale
|
Direct |
9,969
-4.05%
|
$249,225
$25.05 P/Share
|
|
May 24
2021
|
Eric Thomas Schmidt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,897
+11.83%
|
$268,146
$18.22 P/Share
|
|
May 24
2021
|
David D Chang President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,410
+1.17%
|
$493,380
$18.22 P/Share
|
|
May 24
2021
|
Arie Belldegrun Director |
BUY
Exercise of conversion of derivative security
|
Direct |
379,066
+39.4%
|
$6,823,188
$18.22 P/Share
|
|
May 18
2021
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-1.17%
|
$150,000
$30.0 P/Share
|
|
May 18
2021
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.16%
|
$10,000
$2.27 P/Share
|
|
May 18
2021
|
Rafael Amado EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
200,534
+37.42%
|
-
|
|
May 17
2021
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-1.17%
|
$140,000
$28.3 P/Share
|
|
May 17
2021
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.16%
|
$10,000
$2.27 P/Share
|
|
Apr 15
2021
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-1.16%
|
$320,000
$32.32 P/Share
|
|
Apr 15
2021
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.27%
|
$20,000
$2.27 P/Share
|
|
Mar 26
2021
|
Rafael Amado EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
24,866
+15.56%
|
-
|
|
Mar 26
2021
|
Eric Thomas Schmidt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,866
+20.56%
|
-
|
|
Mar 26
2021
|
Alison Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,866
+16.33%
|
-
|
|
Mar 26
2021
|
Veer Bhavnagri General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,202
+5.01%
|
-
|
|
Mar 26
2021
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,452
+3.4%
|
-
|
|
Mar 26
2021
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,635
+20.82%
|
-
|
|
Mar 15
2021
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,053
-10.16%
|
$306,014
$38.23 P/Share
|
|
Mar 15
2021
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
16,623
-1.35%
|
$631,674
$38.03 P/Share
|
|
Mar 15
2021
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.35%
|
$20,000
$2.27 P/Share
|
|
Mar 15
2021
|
Alison Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
6,164
-5.67%
|
$234,232
$38.14 P/Share
|
|
Mar 15
2021
|
David D Chang President and CEO |
SELL
Open market or private sale
|
Direct |
20,513
-0.92%
|
$779,494
$38.57 P/Share
|
|
Mar 15
2021
|
Rafael Amado EVP of R&D |
SELL
Open market or private sale
|
Direct |
2,798
-2.48%
|
$106,324
$38.05 P/Share
|
|
Jan 15
2021
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
15,000
-0.43%
|
$480,000
$32.46 P/Share
|
|
Jan 14
2021
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
15,000
-0.64%
|
$450,000
$30.85 P/Share
|
|
Dec 17
2020
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
51,500
+11.27%
|
$103,000
$2.27 P/Share
|
|
Nov 16
2020
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
15,000
-0.63%
|
$480,000
$32.8 P/Share
|
|
Oct 15
2020
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
15,000
-0.25%
|
$615,000
$41.24 P/Share
|
|
Oct 13
2020
|
Alison Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
11,031
-9.24%
|
$463,302
$42.0 P/Share
|
|
Oct 13
2020
|
Alison Moore Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,031
+8.46%
|
$22,062
$2.27 P/Share
|
|
Oct 12
2020
|
Alison Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
24,233
-18.27%
|
$1,017,786
$42.0 P/Share
|
|
Oct 12
2020
|
Alison Moore Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,233
+15.45%
|
$48,466
$2.27 P/Share
|
|
Oct 09
2020
|
Alison Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
39,509
-26.72%
|
$1,619,869
$41.0 P/Share
|
|
Oct 09
2020
|
Alison Moore Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,199
+16.96%
|
$60,398
$2.27 P/Share
|
|
Oct 08
2020
|
Alison Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
5,065
-4.13%
|
$207,665
$41.0 P/Share
|
|
Oct 08
2020
|
Alison Moore Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,065
+3.96%
|
$10,130
$2.27 P/Share
|
|
Oct 07
2020
|
Rafael Amado EVP of R&D |
SELL
Open market or private sale
|
Direct |
16,538
-12.9%
|
$644,982
$39.4 P/Share
|
|
Oct 06
2020
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-2.75%
|
$400,000
$40.0 P/Share
|
|
Oct 06
2020
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.67%
|
$20,000
$2.27 P/Share
|
|
Oct 06
2020
|
Alison Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
44,574
-27.47%
|
$1,782,960
$40.0 P/Share
|
|
Oct 06
2020
|
Alison Moore Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,264
+17.92%
|
$70,528
$2.27 P/Share
|
|
Oct 01
2020
|
Rafael Amado EVP of R&D |
SELL
Open market or private sale
|
Direct |
9,752
-7.07%
|
$351,072
$36.37 P/Share
|
|
Oct 01
2020
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-2.24%
|
$900,000
$36.99 P/Share
|
|
Oct 01
2020
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+6.19%
|
$50,000
$2.27 P/Share
|
|
Oct 15
2018
|
Pfizer Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
55,556
+0.25%
|
$1,000,008
$18.0 P/Share
|
|
Oct 15
2018
|
Pfizer Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
21,976,484
+50.0%
|
-
|